Invivyd's VYD2311 Phase 3 DECLARATION Study Achieves Sufficient Statistical Power at ~50% Progress; Advances Novel Measles mAb VMS063 into Clinical Development

Key Highlights

• The Phase 3 DECLARATION study for VYD2311, an investigational COVID-19 PrEP, has accumulated sufficient confirmed, pooled, blinded COVID-19 events at approximately 50% study progress to provide statistical power for the high end of anticipated VYD2311 efficacy.
• A pre-specified sample size re-estimation analysis was conducted when 1,500 of 1,818 enrolled patients reached Day 45 of the 90-day total study period, confirming the study is well-powered for its primary endpoint.
• Invivyd is advancing VMS063, a novel monoclonal antibody candidate for measles, into clinical development for both treatment and prevention.
• Preclinical data for VMS063 demonstrated potent neutralization of measles virus and protection in a non-human primate model.
• The advancement of VMS063 addresses the increasing global outbreaks of measles, a highly contagious disease.
• Invivyd plans to provide a more comprehensive update on the REVOLUTION program and VYD2311 data later in 2026.